Follow Up Guidance During COVID-19 Crisis

About the Registry

The STS/ACC TVT RegistryTM , created by a collaboration between the Society for Thoracic Surgeons (STS) and the American College of Cardiology (ACC), monitors patient safety and real-world outcomes related to transcatheter valve replacement and repair procedures – emerging treatments for valve disease patients. Employing state-of-the-art heart valve technology, transcatheter heart valve procedures provide new treatment options for patients who are not eligible for conventional heart valve replacement or repair surgery.

The TVT Registry has been approved by the Centers for Medicare and Medicaid Services (CMS) to meet the registry requirements outlined in the national coverage decisions for transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR)

An Invaluable Data Source

Analysis of TVT Registry data will allow the cardiovascular profession and medical community to understand how transcatheter heart valve procedures are being deployed throughout the U.S., and what impact they will have on patient outcomes as they become more prevalent. Data from the registry will also assist the medical device industry and the FDA in surveillance of the quality, safety and efficacy of new medical devices.

Employing Key Experience and Know-How

Developed through a partnership between the STS and ACC, the TVT Registry is backed by a breadth of expertise and resources. Together, STS and ACC have more than 35 years of registry experience, more than 100 years leading the cardiovascular medicine profession and more than 56,000 members worldwide. Learn more.

The TVT Registry was developed in collaboration with the Federal Drug Administration (FDA), CMS and with input from the Society for Cardiovascular Angiography and Intervention and the American Association for Thoracic Surgery. 


View a list of current TVT Registry participants

Back to Top